{
    "symbol": "BBLN",
    "quarter": 3,
    "year": 2022,
    "date": "2022-11-13 22:20:03",
    "content": " For an adjusted EBITDA standpoint, we expect to exit December 2022 with a monthly adjusted EBITDA loss of less than $18 million and continue to focus on our key drivers towards positive adjusted EBITDA and reducing 2023 monthly adjusted EBITDA loss, specifically, our revenue margin mix, execution of our clinical and technology initiatives that driving claims margin improvements, and a continued focus on driving operational leverage, including execution of current and future cost savings actions."
}